Back to top
more

Evolus (EOLS)

(Delayed Data from NSDQ)

$12.91 USD

12.91
248,311

-0.02 (-0.15%)

Updated Aug 7, 2024 03:59 PM ET

After-Market: $12.92 +0.01 (0.08%) 6:40 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.03%
2Buy17.70%
3Hold9.37%
4Sell5.03%
5Strong Sell2.48%
S&P50011.19%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value A Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 42% (105 out of 250)

Industry: Medical - Products

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biocept (BIOC) to Report Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Biocept (BIOC) is expected to have suffered in Q2 from reduced oncology practices and postponement of patient appointments.

Implied Volatility Surging for Evolus (EOLS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.

Implied Volatility Surging for Evolus (EOLS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.

Kinjel Shah headshot

Allergan (AGN) Surpasses Q4 Earnings and Sales Estimates

by Kinjel Shah

Botox, Juvederm fillers and Vraylar drive Allergan's (AGN) fourth-quarter sales, making up for loss of exclusivity on some brands and lower sales of eye drug, Restasis.

Kinjel Shah headshot

Allergan (AGN) Shareholders Approve Acquisition by AbbVie

by Kinjel Shah

Allergan's (AGN) shareholders give green signal to its pending merger with AbbVie for a transaction value of nearly $63 billion.

What's in Store for Flexible Solutions (FSI) in Q2 Earnings?

by Zacks Equity Research

Our proven model does not show that Flexible Solutions (FSI) is likely to beat estimates this quarter.

Barrick (GOLD) to Post Q2 Earnings: What's in the Cards?

by Zacks Equity Research

Strong performances from Loulo-Gounkoto and Veladero likely to drive Barrick's (GOLD) Q2 results.

Advance Auto Parts (AAP) to Post Q2 Earnings: What's Up?

by Zacks Equity Research

Advance Auto Parts (AAP) Q2 results to gain on footprint expansion. However, high capital expenditures and tough competition make surprise prediction difficult.

Urmimala Biswas headshot

4 Medical Product Stocks Set to Beat This Earnings Season

by Urmimala Biswas

Here we discuss four medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Will Evolus Continue to Surge Higher?

by Zacks Equity Research

As of late, it has definitely been a great time to be an investor Evolus.

AbbVie (ABBV) Shares Down So Far This Year: Here's Why

by Zacks Equity Research

AbbVie's (ABBV) stock suffers a poor run on the bourses due to pipeline setbacks, Humira sales erosion in EU and its proposed offer to buy Allergan.

Allergan Up As Analyst Statement Sparks Business Split Rumors

by Zacks Equity Research

Allergan's (AGN) shares up following a conference call with one of the company's executives, which led an analyst to believe that a split of the company's business is in the cards.

Can Breast Health Growth Drive Hologic's (HOLX) Q2 Earnings?

by Zacks Equity Research

Hologic's (HOLX) Breast Health segment is witnessing a rapid uptick on the back of large installed base of market-leading, clinically differentiated Genius 3D mammography systems.

Will Pharmacy Services Drive CVS Health's (CVS) Q1 Earnings?

by Zacks Equity Research

Within Pharmacy Services, despite a fierce pricing competition, CVS Health (CVS) is currently riding on high level of service and execution, competitive pricing and a unique integrated model.

Will Pricing Pressure Hurt Zimmer Biomet (ZBH) Q1 Earnings?

by Zacks Equity Research

With Zimmer Biomet (ZBH) focusing solely on this restructuring initiative, chances are slim for the company to post promising growth performances across its operating segments.

Can Covance Business Growth Aid LabCorp (LH) in Q1 Earnings?

by Zacks Equity Research

Within Covance Drug Development, LabCorp (LH) is expected to drive profitable growth through expanded solutions and enhanced operational capabilities.

Can iTotal PS Revenues Drive ConforMIS' (CFMS) Q1 Earnings?

by Zacks Equity Research

ConforMIS (CFMS) expects to register solid revenue growth on robust performance by its product lines as well as steady royalties.

Can Front Line Care Drive Hill-Rom's (HRC) Q2 Earnings?

by Zacks Equity Research

Hill-Rom (HRC) consistently reports strong Core revenue growth in domestic and international markets on solid segmental performance.

Can Core Renal Care Unit Drive Baxter's (BAX) Q1 Earnings?

by Zacks Equity Research

Strong performance across Renal Care, Clinical Nutrition, Advanced Surgery and Acute Therapies businesses might aid Baxter (BAX) in Q1. However, lower sales at Pharmaceutical business might be a woe.

Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus

by Zacks Equity Research

Zacks Market Edge Highlights: Edwards Lifesciences, Exact Sciences, Aimmune Therapeutics, Allergan and Evolus

Tracey Ryniec headshot

NASH, Allergies and Beauty Stocks: Invest or Not?

by Tracey Ryniec

There's a lot of innovation going on at the biopharmaceutical companies but which areas should investors be targeting?

Implied Volatility Surging for Evolus (EOLS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.

Allergan Responds to Investor's Call for CEO/Chair Role Split

by Zacks Equity Research

Allergan (AGN) informs that it does not agree with the view of its key shareholder, Appaloosa, to separate the roles of CEO and board chairman.

Allergan Stock Falls as FDA OK's Botox Rival for Frown Lines

by Zacks Equity Research

Allergan's (AGN) stock declines almost 4% after FDA approves Evolus' Jeuveau injection to treat frown lines, which can pose strong competition to Botox.

Implied Volatility Surging for Evolus (EOLS) Stock Options

by Zacks Equity Research

Investors need to pay close attention to Evolus (EOLS) stock based on the movements in the options market lately.